News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Pedram Razavi

Articles by Pedram Razavi

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

ByPedram Razavi,Judith Balmaña,Stephen Luen,Mario Campone,Laura Cortesi,Norikazu Masuda,Kyong Hwa Park,Qingyuan Zhang,Emily Nizialek,Cathy Qi,Karen Cui,Sibylle Loibl,Mark Robson, MD,Filipa Lynce

April 22nd 2025

Latest Updated Articles

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)
April 22nd 2025

Trending on CancerNetwork

Daraxonrasib Shows "Unprecedented" Survival in Pretreated Pancreatic Cancer

What ESO-T01 Tells Us About the Next Frontier in Multiple Myeloma

I-DXd Earns FDA Priority Review in Extensive-Stage Small Cell Lung Cancer

REGN5668 Combo Yields Preliminary Activity in Recurrent Ovarian/Endometrial Cancer

FDA Grants Fast Track Designation to Daretabart for High-Risk Neuroblastoma